A Phase 3 study in the U.S. is planned to start in early 2026 to support a submission for FDA approval. MUNICH, Oct. 1, 2025 /CNW/ -- Vertanical today announced publication of results from two Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback